Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Investor Day (January 2013)
94 slides from Angiodynamics's investor day presentation, Jan 23, 2013
Slide 1: FY 2013 Investor & Analyst Day
AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved. FY 2013 Investor & Analyst Day New York, NY January 23, 2013
Slide 2: Matt Kapusta | SVP, Business Development
AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved. Matt Kapusta | SVP, Business Development
Slide 3: Agenda
Agenda Topic Presenter Strategic Overview Joseph DeVivo, President & CEO Peripheral Vascular John Soto, SVP & Global Business Leader Vascular Access Chuck Greiner, SVP & Global Business Leader Oncology /Surgery Rick Stark, SVP & Global Business Leader Break Financial Overview Mark Frost, EVP & CFO R
Slide 4: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 5: Joseph DeVivo | President and CEO
AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved. Joseph DeVivo | President and CEO
Slide 6: A New Day… Our Vision and Mission
A New Day… OUR VISION: To be recognized, trusted and respected worldwide as a leading provider of innovative image guided, minimally invasive solutions OUR MISSION: We will work each day with integrity and passion to deliver high-quality, innovative, cost-effective solutions that meet the needs of o
Slide 7: Our Core Values
What we will do How we will do it Focus on the patient Live Quality Drive Value for the Customer Innovate Relentlessly Accountability Integrity Collaboration Tempo Our Core Values
Slide 8: Our Strategic Imperatives
Target Investments for Growth Drive Efficiency & Productivity Our Strategic Imperatives 2 We will focus our investments on opportunities that offer sustainable, profitable growth 3 We will enhance our profitability by driving operational excellence across the entire organization Improve Shareholder
Slide 9: Our Strategic Framework
Our Strategic Framework Improve Shareholder Returns Targeted Investments for Growth Drive Efficiencies & Productivity Key Metrics ROCE EPS Growth Cash Flow Generation Australia Latin America China Brazil Japan Innovation New Market Expansion Key Metrics Vitality Index Pipeline Strength Key Metrics I
Slide 10: Our Rapidly Changing Environment
Our Rapidly Changing Environment Regulatory Payers Hospitals Physicians Patients Increasing regulatory scrutiny Increasing pricing pressure and transparency Sluggish procedure volumes Increasing need for clinical and healthcare economic data Greater prevalence of contract purchasing OUR STAKEHOLDERS
Slide 11: Improving Our Competitiveness
Improving Our Competitiveness We are implementing strategies that will enable us to compete more effectively in the current global landscape Generate clinical and healthcare economic data that drive adoption Maintain regulatory compliance Focus on high value, differentiated technologies that support
Slide 12: Execution
Execution Bolstered Management Team New Chief Technology & Ops Officer and senior R&D managers New Heads of Regulatory, Quality, Clinical and Medical Affairs New Chief Financial Officer Increased FY13 synergy targets 40% to $7-10M and to $15M in FY14 Closure of Fremont and optimization of R&D Redu
Slide 13: Improving Business Trends
Improving Business Trends +1% Challenging US sales integration Q4 FY12 channel loading Soft summer procedure volume Lack of tip location Delayed NanoKnife purchases +5 - 8% Increasing BioFlo momentum Launch of AngioVac Improving EVLT business Stabilizing US Sales Channel Strong NanoKnife pipeline 1H
Slide 14: Transformation to a Double-Digit Growth Company
20% of Sales 80% of Sales VenaCure EVLT NanoKnife Int’l Microwave VenaCure EVLT NanoKnife Global Microwave AngioVac BioFlo Fluid Mgmt > 10% Growth < 10% Growth Execution on our key strategic initiatives will drive a fundamental shift in our revenue base towards high growth +10% CAGR < 10% Growth >
Slide 15: Deepening Organizational Capabilities in Clinical and Regulatory
CRITICAL SUCCESS FACTOR Significant investments in our clinical and regulatory capabilities are essential to ensuring successful execution of our strategy Acute awareness of environmental factors Open/direct lines of communication with agencies Proactive/up-stream engagement of FDA Accelerated timel
Slide 16: World Class Quality and Operational Excellence
OUR FOUNDATIONS FOR SUCCESS WILL NOT CHANGE We are intensely focused on delivering world-class quality and operational excellence across all aspects of our business Our goal is to generate an average of 50-100 bps of gross margin improvement each year through FY18 Invest in and cultivate our “cultur
Slide 17: Optimizing Our U.S. Go-to-Market Strategy
Sales force specialization is critical to delivering maximum value to all our customers – physicians, hospitals, GPOs and IDNs Oncology/ Surgery Peripheral Vascular Vascular Access VP Sales Area Sales Director VA Sales Rep PV Sales Rep O/S Sales Rep Regional/ Specialized Selling Teams U.S. Commercia
Slide 18: Increasing Investments in International Expansion
We will accelerate growth internationally by making targeted investments in key markets $50M Mkt 8-10% Growth 4% Share BRAZIL $200M Mkt 10-15% Growth 2% Share CHINA $270M Mkt 3-5% Growth 2% Share JAPAN Sales reps Product Registrations IFUs Clinical Trials Regulatory Product Launches Manufacturing In
Slide 19: Our Financial Aspirations
NEAR-TERM EXPECTATIONS + UPSIDE FROM STRATEGIC IMPERATIVES = LONG-TERM FINANCIAL GOALS Achieve high single digit revenue growth Achieve double digit operating margins Achieve double digit operating income growth Consistent double digit revenue growth Mid-teens operating margin Mid teens operating in
Slide 20: John Soto | SVP – Peripheral Vascular
John Soto | SVP – Peripheral Vascular Global Business Leader AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 21: Peripheral Vascular Overview
Focus on High Margin High Growth Products US-direct Reps and Clinical Specialists Int’l-direct and indirect Global Leader in Laser Venous Ablation Global Leader in Fluid Management Focused R&D Pipeline OUR VISION To be recognized, trusted and respected worldwide as a leader of innovative, cost-effec
Slide 22: Cardiovascular and Venous Disease Market
Cardiovascular Market Venous Disease Market Current US Cardiology Manifold Share Opportunity in WW Cardiovascular $1.3 B Market Peripheral Vascular
Slide 23: Peripheral Vascular 5-Year Growth Strategy
Invest Significantly in the AngioVac Market Drive Greater VenaCure EVLT Adoption Revitalize NAMIC & Launch FM Innovation Strategic Core Line Extensions & BD AngioDynamics’ Peripheral Vascular Long Term Growth Target: 8-12% CAGR 1 3 4 2 Continue Building Critical Mass in the Venous Space Develop Deep
Slide 24: Venous Strategy – Superficial and Deep Systems
Peripheral Vascular Venous Strategy – Leadership Across the Superficial and Deep Systems Achieving leadership in Venous Disease will require focus across both the superficial and deep venous systems DEEP SUPERFICIAL DVTs Varicose Veins Pulmonary Embolisms
Slide 25: Deep Venous Strategy – Thrombus Management
We are creating a deep product portfolio across the Thrombus Management continuum Peripheral Vascular Deep Venous Strategy – Depth in Thrombus Management
Slide 26: The Opportunity – VTE Incidence
Additional: Annual Incidence Venous Thromboembolism (VTE) Incidence Overall ~1 Million VTE Events per Year in US Overall 300,000 VTE Deaths per Year in US - #3 cause Heit JA, et al. Blood. 2005;106:267A. Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012 IVC
Slide 27: The Problem and Current Treatment Options
Venous segment- Largest procedural growth rate 2008 Surgeon Generals Call to Action – DVT and PE Clinical Trials are driving venous disease awareness and treatment (ATTRACT)* The Problem and Current Treatment Options *Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thromb
Slide 28: AngioVac – The Device
A highly differentiated endovascular device Facilitates en bloc removal of undesirable intravascular material Large, established unmet market opportunity FDA cleared, with encouraging early market traction Synergistic call points – cardiac and vascular surgeons, interventionalist Highly attractive p
Slide 29: AngioVac – The Device
AngioVac – The Device Reinfusion Cannula Filter Saline Bag Centrifugal Pump Console AngioVac Cannula AngioVac Circuit The AngioVac devices are for use with other manufacturer’s off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of a extracorporeal bypass proced
Slide 30: AngioVac Procedure
AngioVac Procedure Introducing a AngioVac Cannula and Circuit Designed to facilitate en-bloc removal of undesirable intravascular material during the performance of extracorporeal circulation. ® angiodynamics
Slide 31: VenaCure EVLT
30M People in USA w/ Varicose Veins $240 million Global market; 10-15% CAGR‘ 100,000+ VenaCure EVLT procedures in FY13 ANGO has ~25% share of Venous Ablation market and ~50% share of the Laser Ablation market Installed base of ~4000 units worldwide, including 400+ new 1470 lasers since launch in Jun
Slide 32: Maximizing Two Technologies for Better Patient Outcomes
Maximizing Two Technologies for Better Patient Outcomes… VenaCure EVLT
Slide 33: The Opportunity – Varicose Veins
Prevalence Diagnosed Treated AngioDynamics Seek Treatment 30M 5M 2M .4 .1 (Millions of US Patients) <1% of the population with Varicose Veins receives ANGO therapy Patient/Physician Awareness Reimbursement/Cost Clinical Evidence/QOL Physician Training Product Competitiveness Barriers to treatment Th
Slide 34: Fluid Management Market
AngioDynamics FM Growth GM 2012 GM Target ASP’S ASP’S Fluid Management Market Market is under pressure: Highly competitive ASP Pressure Low margins Conversion to Automation By Automating we will: Rejuvenate growth in margins Create 100M automation business Increase sales +10% Improve margins
Slide 35: NAMIC API Key Features and Benefits
Long learning curve Increased set up time Lack of flow restriction indicator Contrast dosage to the patient Contrast use and waste per procedure Unreliable hemodynamics readings Greater control Reduced per procedure costs Provide greater protection and safety NAMIC API Key Features and Benefits Conc
Slide 36: EVLT Summary
45% 100% 25% AngioVac, EVLT, and Automation will provide the Peripheral Vascular business, Angio’s largest business unit, with three key high margin products geared toward long-term growth 65% 76% 24% Revenue 8-12% CAGR EVLT AngioVac API EVLT Summary
Slide 37: Chuck Greiner | VP – Vascular Access
Chuck Greiner | VP – Vascular Access Global Business Leader AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 38: Vascular Access Overview
Vascular Access VA Product sales in over 50 markets globally US – Direct sales and clinical specialists Int’l – Direct in Canada, UK, Netherlands, France and Germany OUR VISION To become a leader in vascular access by introducing disruptive technologies that will help clinicians reduce catheter-rela
Slide 39: Global Vascular Access Business
Global Vascular Access Business $1B Global Market EU $100M US $700M LAC $90M Dialysis $230M 2-4% CAGR Ports $330M 3-5% CAGR PICCs $450M 5-7% CAGR New markets $115M
Slide 40: Vascular Access 5-Year Growth Strategy
Drive global adoption of BioFlo Increase penetration of IDNs, GPOs and public Tenders Accelerate international expansion Vascular Access Long-term Growth Target: 8-10% CAGR Broaden offering to include tip location Vascular Access 5-Year Growth Strategy 4 3 2 1
Slide 41: BioFlo – The Opportunity
Major Complications 25-33% of access devices occlude 58% of occlusions are a result of thrombosis Significant Costs Average cost for DVT ($9,805) Average cost per readmission ($11,862) CDC guidelines connect thrombosis to infection Thrombosis of vascular access devices leads to major complications a
Slide 42: The BioFlo Solution
The BioFlo Solution Estimated that more than 100 accounts have either converted to or are in the process of evaluating BioFlo The BioFlo Solution
Slide 43: BioFlo – Early Experiences
48% reduction in occlusions 38% reduction in t-PA use 37% reduction in DVT Results from an Int’l Institution Retrospective Analysis BARD PowerPICC Solo2® vs. BioFlo with PASV PICC NOTE: Preliminary retrospective data analysis conducted by independent investigators. BioFlo has been cleared in the U.S
Slide 44: BioFlo – Clinical & Economic PROOF Study
PROOF: The PICC Related Obstruction Of Flow Study Confirming the initial reported data Clinical & Economic impact analysis The PROOF Study BioFlo – Clinical & Economic PROOF Multi center (5) Global Clinical PICC Study
Slide 45: GPOs, IDNs, Public Tenders
VASCULAR ACCESS GPOs, IDNs, public Tenders – Leveraging Our Broad Product Portfolio Currently on contract with the four major US GPO’s & Health Canada Dialysis on the four major GPO’s and PICC/Port on Premier in the US Recently awarded major IDN, expecting announcement this quarter
Slide 46: Accelerating International Expansion
New and Emerging Markets 20-25% CAGR Accelerating International Expansion Int’l Expected Mix (Target) US 75% 25%
Slide 47: Summary
Summary 1 Growing our core BioFlo product line 2 IDN, GPO and public tender penetration 3 Investment in clinical and economic impact data 4 Reaching deep into global markets 5 Broaden offering to include tip location
Slide 48: Rick Stark | SVP – Oncology/Surgery
Rick Stark | SVP – Oncology/Surgery Global Business Leader AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 49: Oncology/Surgery Overview
Oncology/ Surgery O/S High-Growth, High-Margin Product Portfolio US – Direct Sales Channel and Clinical Specialists Int’l – Direct in 5 Countries Focused Clinical Strategy OUR VISION Oncology Surgery will become the leader in ablation through the development and marketing of innovative, proprietary
Slide 50: Acquisition Announcement – Microsulis
Acquisition Announcement fie Microsulis Medical Ltd ¥¥ SPECIALISTS IN MICROWAVE ABLATION d 5 i>) angiodynamics
Slide 51: Microsulis
Microsulis We believe Microsulis is the leading microwave tumor ablation technology on the market today “Everything we wanted in a microwave device…” -Current AngioDynamics RFA Customer 2.45Ghz system for faster tissue penetration Single applicator 5 cm ablation Fast ablation times Predictable volum
Slide 52: Oncology Surgery Five Year Growth Strategy
3 1 2 4 Invest in clinical development Become the standard of care Increase thermal ablation share Invest in innovative product development AngioDynamics’ Oncology Surgery Long Term Growth Target: 15-20% CAGR Create Markets for Non-Thermal Ablation Expand in Thermal Ablation Oncology Surgery Five Ye
Slide 53: Expanding Our Leadership in Tumor Ablation
Angiodynamics offers a full complement of tumor ablation products that provide clinicians maximum choice in treating patients THERMAL NON-THERMAL “The US Nonvascular Interventional Radiology market with the fastest growth and greatest potential is the ablation device market” – MRG Nov. 2012 Expandin
Slide 54: The Device – The Total Ablation System
Microwave IRE Module RF Module Integrates RFA, IRE and MTA into one system First of its kind, modular platform ablation technology Common Graphic User Interface Integrated system controls Enhanced ease of use The Device – The Total Ablation System TAS
Slide 55: TAS - The Opportunity
TAS - The Opportunity angiodynamics StarBurst® REA) Acculis. MTA. Nanoknife A>) angiodynamics
Slide 56: NanoKnife Continues to Gain Traction
NanoKnife Continues to Gain Traction System placements Utilization Clinical publications Clinical Studies
Slide 57: Summary
1 Leader in focal ablation therapies in surgical and interventional oncology 2 Best-in-class ablation modalities – solutions for every patient 3 Significant market opportunities within disease states with high unmet clinical needs 4 Large untapped market potential in focal treatment of pancreas and
Slide 58: Minute Break
10 Minute Break AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 59: Mark Frost | EVP & CFO
Mark Frost | EVP & CFO AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 60: Near Term Priorities
Integrating Navilyst acquisition Leveraging cost synergies Margin expansion through sales leverage Optimizing R&D investment Driving adoption of AngioVac, BioFlo Maximizing US Microwave launch Strong and sustainable cash generation Near Term Priorities
Slide 61: Fiscal 2013 First Half Results
Improve Shareholder Returns Pro Forma (in $M’s) Q2 H1 Net Sales - $’s - Growth rate 87 3% 170.4 1% Peripheral Vascular Growth rate 45.8 3% 89.1 2% Vascular Access Growth rate 26.7 (3%) 53.3 (4%) Oncology/Surgery Growth rate 12 12% 23.2 13% GM% 50.8% 51.5% Operating Income 7.5 14.8 Adjusted EPS 0.10
Slide 62: Financial Outlook – FY13 Guidance
Pro Forma (in $M’s) H2 FY13 Net Sales - $’s - % Growth 185 – 190 7% 355 – 360 4% Gross Margin 50 – 51% 50 – 51% Operating Income 14 - 17 29 - 31 EPS 0.20 – 0.22 0.40 – 0.42 Cash EPS* 0.39 – 0.4 0.73 – 0.75 EBITDA 29 - 30 56 - 57 Moving in the right direction Financial Outlook – FY13 Guidance *Repres
Slide 63: Where we have come from…
Where we have come from… Financial results as reported In Millions
Slide 64: Leaner and Improved Profitability – Operating Expenses
Median = 29% Median = 6% …our Operating Expenses are moving in line with our peer group… Efficiency & Optimization Efficiency & Optimization LOOKING AHEAD… Leaner and Improved Profitability Competitors Competitors
Slide 65: Operating Leverage & Profitable Growth
Median = 16% Median = 22% …and we expect operating margin and EBITDA margins to continue to increase substantially over the next 5 years Operating Leverage & Profitable Growth Operating Leverage & Profitable Growth LOOKING AHEAD… Leaner and Improved Profitability…But more Work to Do Adjusted Operati
Slide 66: Transformation to a Double-Digit Growth Company (FY13)
Fluid Mgmt PICCs Other PV 65% YoY Sales Growth EVLT Ports 0% 5% 10% 15% 20% 40% +50% HARVEST FIX INVEST SCALE Microwave IRE RFA Resection Other VA AngioVac Std GM% FY 2013: 4% Sales Growth; 50% GM% (10%) (5%) Transformation to a Double-Digit Growth Company HIGH LOW
Slide 67: Transformation to a Double-Digit Growth Company (Long-Term)
Ports 0% 5% 10% 15% 20% +50% YoY Sales Growth 40% EVLT AngioVac 65% IRE Resection Other VA Other PV Fluid Mgmt Dialysis Microwave Std GM% PICCs RFA Long-Term: +10% Sales Growth; 60% GM% Transformation to a Double-Digit Growth Company (10%) (5%) HIGH LOW
Slide 68: Factors Driving Improved Financial Performance
Near Term International performance – 20% growth Specific product results: EVLT, NanoKnife, Microwave Sales force productivity, back on offense Move to one operating platform Long Term New product innovation International expansion to new markets Operational excellence Factors Driving Improved Finan
Slide 69: Summary
Optimized R&D organization to accelerate new product pipeline Acquired new products like AngioVac, microwave with high growth potential Significantly improving quality management systems Continued rapid growth of International platform Drive for operational excellence Stronger executive management t
Slide 70: Lou Mazzarese | SVP – Chief Regulatory Officer
Lou Mazzarese | SVP – Chief Regulatory Officer AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 71: FDA - Current Environment
AngioDynamics Regulatory Imperatives Medical Device User Fee Re-Authorization (MDUFA III) Expanded product Indications for Use FDA - Current Environment
Slide 72: Current Environmental Factors
Rx and Med Device Product Problems FDA reviewer unrest Consumer Activism Changing Political Landscape / Pressure Legislative / Administrative Initiatives – 2012 MDUFA User Fees Current Environmental Factors
Slide 73: Regulatory Strategic Imperatives
Acute awareness of environmental factors Open/Direct lines of communication with regulatory agencies Proactive/Up-stream engagement of FDA Accelerated timelines for new product approvals Minimize potential for interruption in product availability due to regulatory issues Regulatory Strategic Imperat
Slide 74: FDA 2012 User Submission Fee
Additional review and supervisory personnel Structured process for pre-submission meetings FDA feedback does not change unless new issues arise Substantive Interactions FDA feedback midway in review process FDA days to decision goals Meeting with FDA to discuss timeline for reaching decision FDA 201
Slide 75: Global Regulatory Focus
* Consolidation of Notified Body support in order to streamline CE Mark product registration and approvals Establishment of more direct product registration processes for BRIC countries (Brazil, Russia, India, China), Asia-Pac and Mexico Completion of European CE Mark for AngioVac, including expande
Slide 76: Expanded Product Indications for Use
NanoKnife for use in treating tumors of the pancreas AngioVac for use in removing thrombus and clots Use of BioFlo products demonstrating significant reduction in procedure related thrombus and clotting Expanded Product Indications for Use
Slide 77: Dr. Frank Facchini | Medical Director
Dr. Frank Facchini | Medical Director AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 78: PROOF Study Protocol
Protocol Title: PROOF: The PICC Related Obstruction Of Flow Study Purpose: To investigate whether the BioFlo PICC will be associated with a reduced incidence of catheter-related venous thrombosis (symptomatic and asymptomatic) compared to another commercially available PICC. Design: Randomized, Mult
Slide 79: INSPIRE Study Protocol
Protocol Title: INSPIRE: A Safety Study to Investigate NanoKnife Surgery in Stage II Pancreatic Cancer with IRE (Irreversible Electroporation) Purpose: To confirm that the NanoKnife system is safe for use within the pancreas. Design: Single Arm, Multi-center Enrollment: 20 patients / 3 sites Study O
Slide 80: CROES Study Protocol
Protocol Title: CROES: The safety and efficacy of Irreversible Electroporation for the ablation of prostate cancer assessed by procedural related side effects and post prostatectomy histology: A Prospective Human In-Vivo Study Purpose: To assess the safety, efficacy, and patient satisfaction of IRE
Slide 81: George Bourne | Chief Technology & Operations Officer
George Bourne | SVP and Chief Technology & Operations Officer AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 82: R&D Executive Summary
GOAL: Angiodynamics R&D will deliver innovative, high quality product solutions for the treatment of vascular access, peripheral vascular and oncology disease states providing superior outcomes and reduced healthcare costs, in the following ways: Refined Organizational Structure to align with 3 busi
Slide 83: Focus is on Breakthrough & New Platform Programs
Focus is on Breakthrough & New Platform Programs
Slide 84: R&D and Clinical Innovation Drives Overall Growth
R&D and Clinical Innovation Drives Overall Growth Near Term (FY13-14) Mid Term (FY15-16) Long Term (FY17-18) BioFlo™ Expanded Platforms Expanded Port Offering Tip Location BioFlo PICC (PROOF) Study PICC Placement Tools Next Generation Ports Optimized Procedural Kits BioFlo Dialysis Study Next Genera
Slide 85: Automated Power Injector Product Development
Automated fluid management injector that allows the clinical to monitor invasive pressures and inject fluids during angiographic procedures. System consists of: Injector: bed/floor/ceiling mount or cart options Display screen Multi-use disposables: cartridge, hand-controller & foot pedal Single-use
Slide 86: BioFlo Technology Product Development
Vascular Access BioFlo Technology Breakthrough technology designed to reduce the accumulation of catheter related thrombus Includes a robust technology Integrated throughout catheter shaft Extended Durability Excellent Mechanical Integrity Exceptional Chemical Resistance Ability to leverage into a v
Slide 87: How the BioFlo Technology Compares
Catheter Wall Coating (Blue) Catheter Wall Impregnated Agent (Gold) Catheter Wall Coatings (On the surface) Impregnated (In the pores) BioFlo Technology (Throughout catheter material) Unlike other technologies that are superficial and/or transient, the BioFlo material is designed to be both integral
Slide 88: AngioVac Next Generation
Peripheral Vascular AngioVac Next Generation Innovative solution for the treatment of Venous Thrombembolism (VTE) (# 3 cause of deaths in US per year*) Expand the current technology platform with: Enhancements Multi-Port working channel hub for multiple accessory device introduction and use Improvem
Slide 89: Mechanical Thrombectomy Device
*Heit JA, et al. Blood. 2005;106:267A. Murphy SL, et al. Deaths: Preliminary Data for 2010. National Vital Statistics Reports; 2012. Peripheral Vascular Mechanical Thrombectomy Device treats peripheral venous (DVT) applications. Design concepts include: Nitinol basket delivered through sheath and ex
Slide 90: Oncology Total Ablation Solution
Microwave IRE Module RF Module Modular energy work station that incorporates IRE, RF, and microwave ablation platforms onto a single cart User Benefits include: Stacked configuration reduces surgical suite footprint Modular design improves flexibility and cost optimization Product Features: Cart app
Slide 91: Key Takeaway: Well-Positioned for Growth
GOAL: Angiodynamics R&D will deliver innovative, high quality product solutions for the treatment of vascular access, peripheral vascular and oncology disease states providing superior outcomes and reduced healthcare costs, in the following ways: Refined Organizational Structure to align with 3 busi
Slide 92: Joseph DeVivo | President and CEO
Joseph DeVivo | President and CEO AngioDynamics, the AngioDynamics logo and other trademarks displayed in this presentation are trademarks owned and used by AngioDynamics, Inc. © Copyright 2012 AngioDynamics, Inc. All rights reserved.
Slide 93: We Are In Position to Drive Shareholder Value
EXECUTION OUR GROWTH DRIVERS NanoKnife New Registrations in Existing Mkts AngioVac API EVLT BioFlo Tip Location Microwave/ TAS China, Brazil & Japan Specialization GPO/IDNs/ Tenders Achieve high single digit revenue growth Achieve double digit operating margins Achieve double digit operating income
Slide 94: Questions
® angiodynamics ' Questions | [AngioDynamicsthe AngioDynamicsogoand othertrademarkedisplavedinthis presentatiorare trademarksownedand used by AngioDynamicsine. © Copyright2012éngloDynamics/nc. All rightsreserved